Soleno Therapeutics, Inc.
SLNONASDAQHealthcare
$53.01
+$0.00(+0.00%)
Market Cap$2.8B
P/E Ratio—
52W High$90.3199
52W Low$29.43
Soleno Therapeutics, Inc. (SLNO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SLNO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.59
Est. $0.73 · -19.2%
Revenue
$0.09B
Est. $0.09B · +0.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
SLNO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.00B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.00B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.91 | — | — | — | $0.11B | — |
| ▼ Q2 FY2026 | May 7, 2026 | $0.73 | $0.59 | -19.2% | $0.09B | $0.09B | +0.9% |
| ▲ Q1 FY2026 | Feb 25, 2026 | $0.64 | $0.80 | +25.0% | $0.09B | $0.09B | +3.4% |
| ▲ Q4 FY2025 | Nov 4, 2025 | $0.06 | $0.47 | +717.4% | $0.07B | $0.09B | -25.4% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.53 | -$0.09 | +83.0% | $0.03B | $0.04B | -17.0% |
| ▲ Q2 FY2025 | May 7, 2025 | -$1.14 | -$0.95 | +16.7% | — | — | — |
| ▼ Q1 FY2025 | Feb 27, 2025 | -$0.63 | -$1.27 | -101.6% | — | — | — |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$0.61 | -$1.83 | -200.0% | — | — | — |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.91
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
$0.59
EPS Est.
$0.73
EPS Surpr.
-19.2%
Revenue
$0.09B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
$0.80
EPS Est.
$0.64
EPS Surpr.
+25.0%
Revenue
$0.09B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$0.47
EPS Est.
$0.06
EPS Surpr.
+717.4%
Revenue
$0.07B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.53
EPS Surpr.
+83.0%
Revenue
$0.03B
Q2 FY2025
May 7, 2025Beat
EPS Actual
-$0.95
EPS Est.
-$1.14
EPS Surpr.
+16.7%
Revenue
—
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
-$1.27
EPS Est.
-$0.63
EPS Surpr.
-101.6%
Revenue
—
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$1.83
EPS Est.
-$0.61
EPS Surpr.
-200.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2028 | $6.86 | $7.33 | $8.15 | 3 |
| Q1 FY2028 | $6.86 | $7.33 | $8.15 | 3 |
| Q4 FY2027 | $1.91 | $2.04 | $2.26 | 2 |
| Q3 FY2027 | $1.64 | $1.76 | $1.95 | 2 |
| Q2 FY2027 | $1.50 | $1.61 | $1.79 | 2 |
| Q1 FY2027 | $1.21 | $1.29 | $1.44 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.8B | $0.8B | $0.9B | 1 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.1B | $0.2B | $0.2B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -19.2% | $52.94 | $52.95 | +0.02% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +25.0% | $39.16 | $41.01 | +4.72% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +717.4% | $65.65 | $63.85 | -2.74% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +83.0% | $81.63 | $81.19 | -0.54% |
| ▲ Q2 FY2025 | May 7, 2025 | +16.7% | $73.71 | $74.66 | +1.29% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -101.6% | $45.10 | $44.99 | -0.24% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -200.0% | $56.39 | $56.86 | +0.83% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +9.5% | $46.73 | $43.96 | -5.93% |
Q2 FY2026+0.02%
Report Date
May 7, 2026
EPS Beat/Miss
-19.2%
Price Before
$52.94
Price After
$52.95
Q1 FY2026+4.72%
Report Date
Feb 25, 2026
EPS Beat/Miss
+25.0%
Price Before
$39.16
Price After
$41.01
Q4 FY2025-2.74%
Report Date
Nov 4, 2025
EPS Beat/Miss
+717.4%
Price Before
$65.65
Price After
$63.85
Q3 FY2025-0.54%
Report Date
Aug 6, 2025
EPS Beat/Miss
+83.0%
Price Before
$81.63
Price After
$81.19
Q2 FY2025+1.29%
Report Date
May 7, 2025
EPS Beat/Miss
+16.7%
Price Before
$73.71
Price After
$74.66
Q1 FY2025-0.24%
Report Date
Feb 27, 2025
EPS Beat/Miss
-101.6%
Price Before
$45.10
Price After
$44.99
Q4 FY2024+0.83%
Report Date
Nov 6, 2024
EPS Beat/Miss
-200.0%
Price Before
$56.39
Price After
$56.86
Q3 FY2024-5.93%
Report Date
Aug 7, 2024
EPS Beat/Miss
+9.5%
Price Before
$46.73
Price After
$43.96
Avg Beat Reaction-0.64%
Avg Miss Reaction+0.20%
Beat Rate5 / 8 quarters
Largest Move-5.93% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SLNO ends December
Soleno Therapeutics, Inc. (SLNO) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.59 — missing the analyst consensus of $0.73 by -19.2%. The next SLNO earnings date is expected around September 1, 2026.
Each quarter, investors track SLNO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SLNO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SLNO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SLNO earnings · 5 questionsSoleno Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. SLNO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SLNO historically reports after market close (AMC).
SLNO earnings datewhen is SLNO earningsSLNO next earnings datewhen does SLNO report earningsSLNO earnings calendar
▸ Source: FMP · Soleno Therapeutics, Inc. SEC filings · US GAAP · Soleno Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026